Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cangrelor Advisory Cmte. Unsure Whether Plavix Even Needs Replacing

Executive Summary

After a brutal panel review, The Medicines Co.’s best chance for its anti-clotting medication may be to create a “better sense of the unmet need” in the perioperative setting when Plavix use must be suspended.

You may also be interested in...

Cangrelor Survives Second Advisory Committee, But Narrowly

FDA panel members were not enthusiastic about the antiplatelet, but felt it could help ‘some people.’

The Medicines Co.’s Slimmer Cangrelor Filing Slated For April Panel Review

Company believes it has addressed all of FDA’s concerns in an April 2014 “complete response” letter relative to use during percutaneous coronary intervention, the only indication that will be the focus of a second advisory committee review.

FDA’s Cangrelor “Complete Response” Leaves Room For Approval Without New Trial

Agency requests additional analyses, but not a new study, supporting the antiplatelet’s use in patients undergoing percutaneous coronary intervention, The Medicines Co. says. However, a second indication in stent thrombosis patients who must stop oral antiplatelet therapy would require a new outcomes trial.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts